Air Liquide has signed a partnership with IDF Europe (International Diabetes Federation European Region) to support organisations advancing diabetes care.

The Tier One corporation will support the company in its advocacy and awareness-raising activities targeting people affected by this chronic illness, the society and policymakers in Europe. Air Liquide’s support also aims to advance diabetes research.

“Through this partnership, Air Liquide intends to contribute to informing as many people as possible about diabetes-related issues and support research in this area. Accordingly, the Group will support IDF Europe’s communication and awareness-raising actions as well as the 2018 Young Researcher Prize. The purpose of the latter is to reward the work of a young researcher under 40 who is involved in research aimed at improving our knowledge of diabetes,” the French company explained.

As part of its home healthcare business, Air Liquide takes care of numerous diabetic patients in Europe to help them improve their lives with the disease. The partnership with IDF Europe illustrates Air Liquide’s long-standing commitment to people suffering from chronic diseases and healthcare professionals, as well as its willingness to strengthen dialogue with the different stakeholders.

As a major public health issue, diabetes is a chronic illness that affects 425 million adults worldwide, 5.6% of the world’s population. Today, 212 million people are still unaware that they have this disease. IDF Europe brings together 70 national organisations from 46 countries and gives a voice to people with diabetes, as well as the greater community and healthcare professionals, to encourage improvements in diabetes prevention, care, and treatment at the European level.